Tirzepatide
Snapshot
Tirzepatide is making waves as the next evolution in diabetes and weight loss medication. As the first dual GIP and GLP-1 receptor agonist, it’s redefining what’s possible—earning FDA approval under brand names like Mounjaro and Zepbound. Here’s a quick look at why it’s leading the next chapter.
Patented
2016
FDA Approval
2022
Body Fat Loss Avg.
26.6%
Annual Sales (2030)
$26B+
*projected numbers based on specific research and studies. Body Fat Loss was over 88 weeks.
The Rise of Zepbound
With both GIP and GLP-1 in play, tirzepatide fuels Mounjaro and Zepbound—and it’s quickly catching up to the semaglutide surge.
What Is the GLP-1 Hormone?
GLP-1 is a natural hormone that helps regulate blood sugar, slow digestion, and signal fullness to the brain—all of which play a key role in managing weight and glucose levels. While GLP-1 is the hormone your body produces, GLP-1 medications are called "agonists" because they mimic and activate the same receptors—essentially extending and enhancing the effects your body would normally trigger after a meal.
What Is Mounjaro?
Mounjaro is an FDA-approved medication that uses tirzepatide to help manage type 2 diabetes. It works by activating both GIP and GLP-1 receptors to improve blood sugar control. Though designed for diabetes, its weight loss effects have drawn widespread attention, leading to further use in obesity treatment under Zepbound.Technically, Ozempic is not FDA-approved for weight loss. However, doctors can prescribe it “off-label” for weight loss.
What Is GIP?
GIP stands for glucose-dependent insulinotropic polypeptide. It’s a natural hormone that helps regulate insulin after meals. When combined with GLP-1 in medications like tirzepatide, GIP may enhance blood sugar control and improve weight loss by acting on different parts of the body, including the brain and fat tissue.
What Is Zepbound?
Zepbound is an FDA-approved weight loss medication that contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It helps regulate appetite, blood sugar, and fat metabolism. Originally used in diabetes treatment as Mounjaro, Zepbound is now making headlines for its powerful results in treating obesity and promoting sustained weight loss.
Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a once-weekly injectable medication that uniquely targets both GLP-1 and GIP receptors. This dual-action mechanism enhances insulin secretion, suppresses appetite, and slows gastric emptying, leading to superior blood sugar control and greater weight loss compared to GLP-1-only drugs like semaglutide.
Tirzepatide
